# üìò 100 Topics for ChEMBL_35 Applications in Drug Discovery

### 1. QSAR model building from ChEMBL IC50 data
- **Ti·∫øng Vi·ªát:** X√¢y d·ª±ng m√¥ h√¨nh QSAR t·ª´ d·ªØ li·ªáu IC50 trong ChEMBL

### 2. Predicting bioactivity from molecular descriptors
- **Ti·∫øng Vi·ªát:** D·ª± ƒëo√°n ho·∫°t t√≠nh sinh h·ªçc t·ª´ c√°c ƒë·∫∑c tr∆∞ng ph√¢n t·ª≠

### 3. Extracting lead-like compounds
- **Ti·∫øng Vi·ªát:** Tr√≠ch xu·∫•t c√°c h·ª£p ch·∫•t gi·ªëng lead

### 4. Filtering rule-of-five compliant molecules
- **Ti·∫øng Vi·ªát:** L·ªçc c√°c ph√¢n t·ª≠ tu√¢n th·ªß quy t·∫Øc Lipinski

### 5. Analyzing drug-likeness using RDKit
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch t√≠nh gi·ªëng thu·ªëc b·∫±ng RDKit

### 6. Virtual screening based on ChEMBL targets
- **Ti·∫øng Vi·ªát:** S√†ng l·ªçc ·∫£o d·ª±a tr√™n c√°c target trong ChEMBL

### 7. Ligand-based drug design using ChEMBL
- **Ti·∫øng Vi·ªát:** Thi·∫øt k·∫ø thu·ªëc d·ª±a tr√™n ligand t·ª´ ChEMBL

### 8. Structure-Activity Relationship (SAR) mining
- **Ti·∫øng Vi·ªát:** Khai th√°c m·ªëi quan h·ªá c·∫•u tr√∫c ‚Äì ho·∫°t t√≠nh (SAR)

### 9. Tanimoto similarity search using ChEMBL + RDKit
- **Ti·∫øng Vi·ªát:** T√¨m ki·∫øm t∆∞∆°ng ƒë·ªìng Tanimoto v·ªõi ChEMBL v√† RDKit

### 10. Chemical space mapping of ChEMBL molecules
- **Ti·∫øng Vi·ªát:** B·∫£n ƒë·ªì kh√¥ng gian h√≥a h·ªçc c·ªßa c√°c ph√¢n t·ª≠ ChEMBL

### 11. Predicting LogP and TPSA of ChEMBL compounds
- **Ti·∫øng Vi·ªát:** D·ª± ƒëo√°n LogP v√† TPSA c·ªßa c√°c h·ª£p ch·∫•t ChEMBL

### 12. Screening for CNS-active drugs
- **Ti·∫øng Vi·ªát:** S√†ng l·ªçc thu·ªëc t√°c ƒë·ªông h·ªá th·∫ßn kinh trung ∆∞∆°ng

### 13. Scaffold hopping analysis
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch thay ƒë·ªïi khung h√≥a h·ªçc (scaffold hopping)

### 14. Prioritizing compounds for synthesis
- **Ti·∫øng Vi·ªát:** ∆Øu ti√™n h·ª£p ch·∫•t cho qu√° tr√¨nh t·ªïng h·ª£p

### 15. Designing focused libraries from ChEMBL
- **Ti·∫øng Vi·ªát:** Thi·∫øt k·∫ø th∆∞ vi·ªán h√≥a h·ªçc t·∫≠p trung t·ª´ ChEMBL

### 16. Finding natural product-like molecules
- **Ti·∫øng Vi·ªát:** T√¨m c√°c ph√¢n t·ª≠ gi·ªëng s·∫£n ph·∫©m t·ª± nhi√™n

### 17. Mining kinase inhibitors from ChEMBL
- **Ti·∫øng Vi·ªát:** Khai th√°c ch·∫•t ·ª©c ch·∫ø kinase t·ª´ ChEMBL

### 18. Target prediction for orphan molecules
- **Ti·∫øng Vi·ªát:** D·ª± ƒëo√°n m·ª•c ti√™u cho c√°c ph√¢n t·ª≠ kh√¥ng r√µ target

### 19. Linking ChEMBL with DrugBank for repurposing
- **Ti·∫øng Vi·ªát:** K·∫øt n·ªëi ChEMBL v·ªõi DrugBank ƒë·ªÉ t√°i ƒë·ªãnh h∆∞·ªõng thu·ªëc

### 20. Comparing ChEMBL scaffolds with FDA drugs
- **Ti·∫øng Vi·ªát:** So s√°nh khung h√≥a h·ªçc ChEMBL v·ªõi thu·ªëc FDA

### 21. Top 50 protein targets by activity count
- **Ti·∫øng Vi·ªát:** 50 protein m·ª•c ti√™u c√≥ nhi·ªÅu ho·∫°t t√≠nh nh·∫•t

### 22. Analyzing GPCR-targeted ligands
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch ligand nh·∫Øm GPCR

### 23. Extracting kinase-binding molecules
- **Ti·∫øng Vi·ªát:** Tr√≠ch xu·∫•t h·ª£p ch·∫•t g·∫Øn kinase

### 24. Target class distribution in ChEMBL
- **Ti·∫øng Vi·ªát:** Ph√¢n b·ªë c√°c nh√≥m target trong ChEMBL

### 25. Multi-target ligand profiling
- **Ti·∫øng Vi·ªát:** L·∫≠p h·ªì s∆° ligand ƒëa ƒë√≠ch

### 26. Correlating bioactivity with target taxonomy
- **Ti·∫øng Vi·ªát:** Li√™n h·ªá ho·∫°t t√≠nh v·ªõi ph√¢n lo·∫°i target

### 27. Disease association of ChEMBL targets
- **Ti·∫øng Vi·ªát:** M·ªëi li√™n h·ªá gi·ªØa target v√† b·ªánh h·ªçc

### 28. Ortholog mapping of targets (human ‚Üí mouse)
- **Ti·∫øng Vi·ªát:** √Ånh x·∫° protein gi·ªØa ng∆∞·ªùi v√† chu·ªôt

### 29. Target pathway analysis via UniProt/KEGG
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch pathway c·ªßa target b·∫±ng UniProt/KEGG

### 30. Binding site comparison across targets
- **Ti·∫øng Vi·ªát:** So s√°nh v·ªã tr√≠ g·∫Øn ligand gi·ªØa c√°c target

### 31. 3D target structure availability from PDB
- **Ti·∫øng Vi·ªát:** Kh·∫£ nƒÉng truy xu·∫•t c·∫•u tr√∫c 3D c·ªßa target t·ª´ PDB

### 32. Predicting binding modes via molecular docking
- **Ti·∫øng Vi·ªát:** D·ª± ƒëo√°n c√°ch th·ª©c g·∫Øn ligand b·∫±ng docking

### 33. Sequence similarity clustering of targets
- **Ti·∫øng Vi·ªát:** Ph√¢n nh√≥m target theo t∆∞∆°ng ƒë·ªìng chu·ªói

### 34. Heatmap of target-ligand interaction count
- **Ti·∫øng Vi·ªát:** Bi·ªÉu ƒë·ªì nhi·ªát v·ªÅ s·ªë l∆∞·ª£ng ligand t∆∞∆°ng t√°c target

### 35. ChEMBL target network visualization
- **Ti·∫øng Vi·ªát:** Tr·ª±c quan h√≥a m·∫°ng l∆∞·ªõi target

### 36. Target enrichment from gene sets
- **Ti·∫øng Vi·ªát:** L√†m gi√†u target t·ª´ b·ªô gene

### 37. Mining antimicrobial targets in ChEMBL
- **Ti·∫øng Vi·ªát:** Khai th√°c target kh√°ng khu·∫©n t·ª´ ChEMBL

### 38. Visualization of protein families
- **Ti·∫øng Vi·ªát:** Tr·ª±c quan h√≥a h·ªç protein t·ª´ ChEMBL

### 39. Finding targets with dual antagonist/agonist activity
- **Ti·∫øng Vi·ªát:** T√¨m target c√≥ ho·∫°t t√≠nh ƒë·ªëi kh√°ng v√† ƒë·ªìng v·∫≠n

### 40. Top viral/bacterial targets in ChEMBL
- **Ti·∫øng Vi·ªát:** C√°c target virus/vi khu·∫©n ph·ªï bi·∫øn nh·∫•t

### 41. Linking ChEMBL drugs to clinical phases
- **Ti·∫øng Vi·ªát:** Li√™n k·∫øt d·ªØ li·ªáu thu·ªëc v·ªõi c√°c pha l√¢m s√†ng

### 42. Drugs with most activity data
- **Ti·∫øng Vi·ªát:** Thu·ªëc c√≥ nhi·ªÅu d·ªØ li·ªáu ho·∫°t t√≠nh nh·∫•t

### 43. Predicting clinical success from early bioactivity
- **Ti·∫øng Vi·ªát:** D·ª± ƒëo√°n kh·∫£ nƒÉng th√†nh c√¥ng l√¢m s√†ng

### 44. Time-to-market estimation using ChEMBL history
- **Ti·∫øng Vi·ªát:** ∆Ø·ªõc l∆∞·ª£ng th·ªùi gian ra th·ªã tr∆∞·ªùng t·ª´ ChEMBL

### 45. Mapping ChEMBL drugs to WHO ATC codes
- **Ti·∫øng Vi·ªát:** √Ånh x·∫° thu·ªëc ChEMBL sang m√£ ATC c·ªßa WHO

### 46. Drug repurposing candidates from ChEMBL
- **Ti·∫øng Vi·ªát:** C√°c thu·ªëc ti·ªÅm nƒÉng t√°i ƒë·ªãnh h∆∞·ªõng

### 47. Comparing clinical vs. preclinical molecules
- **Ti·∫øng Vi·ªát:** So s√°nh thu·ªëc l√¢m s√†ng v√† ti·ªÅn l√¢m s√†ng

### 48. Linking ChEMBL with clinicaltrials.gov
- **Ti·∫øng Vi·ªát:** Li√™n k·∫øt ChEMBL v·ªõi d·ªØ li·ªáu th·ª≠ nghi·ªám l√¢m s√†ng

### 49. FDA-approved ChEMBL drugs analysis
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch thu·ªëc ChEMBL ƒë√£ ƒë∆∞·ª£c FDA ph√™ duy·ªát

### 50. Trends in target class approval
- **Ti·∫øng Vi·ªát:** Xu h∆∞·ªõng ph√™ duy·ªát theo nh√≥m target

### 51. Withdrawn drugs and their ChEMBL profiles
- **Ti·∫øng Vi·ªát:** H·ªì s∆° thu·ªëc b·ªã r√∫t kh·ªèi th·ªã tr∆∞·ªùng

### 52. Oncology-focused drug trend in ChEMBL
- **Ti·∫øng Vi·ªát:** Xu h∆∞·ªõng thu·ªëc ung th∆∞ trong ChEMBL

### 53. Antiviral compounds mapping to COVID-19 targets
- **Ti·∫øng Vi·ªát:** Ph√¢n t·ª≠ kh√°ng virus t∆∞∆°ng ·ª©ng v·ªõi ƒë√≠ch COVID-19

### 54. Neuropsychiatric drug insights from ChEMBL
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch thu·ªëc th·∫ßn kinh ‚Äì t√¢m th·∫ßn

### 55. Drug safety flags and bioactivity profile
- **Ti·∫øng Vi·ªát:** C·∫£nh b√°o an to√†n li√™n k·∫øt v·ªõi ho·∫°t t√≠nh sinh h·ªçc

### 56. Comparing ChEMBL drugs with WHO Essential Medicines
- **Ti·∫øng Vi·ªát:** So s√°nh ChEMBL v·ªõi danh m·ª•c thu·ªëc thi·∫øt y·∫øu WHO

### 57. Pharmacovigilance risk signals in ChEMBL
- **Ti·∫øng Vi·ªát:** D·ªØ li·ªáu t√≠n hi·ªáu c·∫£nh b√°o d∆∞·ª£c l√Ω

### 58. Pediatric drug insights from ChEMBL
- **Ti·∫øng Vi·ªát:** Ph√¢n t√≠ch thu·ªëc d√†nh cho tr·∫ª em

### 59. Orphan drug discovery via ChEMBL
- **Ti·∫øng Vi·ªát:** Kh√°m ph√° thu·ªëc hi·∫øm t·ª´ ChEMBL

### 60. ChEMBL ‚Üí Real-world evidence mapping
- **Ti·∫øng Vi·ªát:** Li√™n k·∫øt d·ªØ li·ªáu ChEMBL v·ªõi d·ªØ li·ªáu th·ª±c t·∫ø

### 61. Topic 61
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 61

### 62. Topic 62
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 62

### 63. Topic 63
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 63

### 64. Topic 64
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 64

### 65. Topic 65
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 65

### 66. Topic 66
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 66

### 67. Topic 67
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 67

### 68. Topic 68
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 68

### 69. Topic 69
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 69

### 70. Topic 70
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 70

### 71. Topic 71
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 71

### 72. Topic 72
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 72

### 73. Topic 73
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 73

### 74. Topic 74
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 74

### 75. Topic 75
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 75

### 76. Topic 76
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 76

### 77. Topic 77
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 77

### 78. Topic 78
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 78

### 79. Topic 79
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 79

### 80. Topic 80
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 80

### 81. Topic 81
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 81

### 82. Topic 82
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 82

### 83. Topic 83
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 83

### 84. Topic 84
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 84

### 85. Topic 85
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 85

### 86. Topic 86
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 86

### 87. Topic 87
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 87

### 88. Topic 88
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 88

### 89. Topic 89
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 89

### 90. Topic 90
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 90

### 91. Topic 91
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 91

### 92. Topic 92
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 92

### 93. Topic 93
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 93

### 94. Topic 94
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 94

### 95. Topic 95
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 95

### 96. Topic 96
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 96

### 97. Topic 97
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 97

### 98. Topic 98
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 98

### 99. Topic 99
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 99

### 100. Topic 100
- **Ti·∫øng Vi·ªát:** Ch·ªß ƒë·ªÅ 100
